The Biosimilar 'Third Wave' of 2026 — Opportunities from the Patent Cliff
The global biopharmaceutical market is approaching an unprecedented inflection point. Between 2025 and 2030, patents on more than 200 blockbuster biologics will expire, with revenue exposure exceeding $236 billion. The so-called 'third wave of biosimilars' is now fully underway.
Key products approaching patent expiry include:
What makes this even more striking is the pipeline gap in the U.S. market. Of approximately 120 reference biologics listed with the FDA, 106 products (roughly 90%) have no biosimilar pipeline whatsoever. This represents vast white space — a first-mover opportunity for agile small and mid-sized biotech firms.
Regulatory Innovation — Phase 3 Waivers and Accelerated Review
The regulatory landscape, historically the tallest barrier to biosimilar development, is undergoing transformative change starting in 2026.
Global Regulatory Developments
These regulatory reforms are expected to lower biosimilar development costs from the historical 70–80% of originator costs to below 50%, meaningfully reducing the capital threshold for market entry by smaller firms.
Five Market Entry Strategies for SME Biotech Companies
1. Leverage CDMOs to Minimize Manufacturing Investment
Building a biologics manufacturing facility typically requires investments of $200–400 million or more. SMEs can strategically utilize CDMOs (Contract Development and Manufacturing Organizations) to minimize upfront capital requirements. Korea's upcoming CDMO Special Act, expected to take effect in 2026, will provide tax incentives and streamlined regulatory pathways for CDMO-based production, further improving the economics of outsourced manufacturing.
2. Target Uncontested Niche Products
Large biosimilar companies tend to concentrate on the top 10 revenue-generating biologics. Meanwhile, mid-tier products with $1–3 billion in annual sales and specialty indications in ophthalmology or rare diseases face limited competition. Systematically screening the 106 pipeline-free products for alignment with existing technology platforms is critical.
3. Global Expansion Through Licensing and Partnerships
Rather than building proprietary commercial infrastructure abroad, technology licensing and co-development partnerships offer a capital-efficient route to global markets. Southeast Asian and Latin American markets, where biosimilar demand is surging, have shown strong interest in Korean biotech capabilities.
4. Maximize Government R&D Funding
With strategic planning from the proposal stage, companies can cover 50–75% of development costs through government grants.
5. Proactive GMP Certification Preparation
GMP compliance remains the final gateway to biosimilar commercialization. Companies should actively utilize the MFDS pre-consultation system to incorporate GMP requirements from the facility design stage and engage with the Global GMP Implementation Technology Support Consortium to simultaneously meet U.S. cGMP and EU GMP standards.
KITIM Consulting — Biosimilar Commercialization Support
KITIM provides end-to-end support for SME biotech companies preparing to enter the biosimilar market, including GMP certification consulting, international regulatory strategy, government R&D grant applications and project planning, and business plan development and investment strategy. The window of opportunity created by the patent cliff is finite. Connect with our experts today to build your market entry strategy.
Contact: [Schedule a Consultation](/en/contact) | Free consultation available